Achilles Therapeutics Plc Stock Performance
| ACHL Stock | USD 1.12 0.01 0.88% |
Achilles Therapeutics has a performance score of 5 on a scale of 0 to 100. The firm shows a Beta (market volatility) of -0.0749, which signifies not very significant fluctuations relative to the market. As returns on the market increase, returns on owning Achilles Therapeutics are expected to decrease at a much lower rate. During the bear market, Achilles Therapeutics is likely to outperform the market. Achilles Therapeutics PLC right now shows a risk of 2.65%. Please confirm Achilles Therapeutics PLC information ratio, downside variance, day median price, as well as the relationship between the treynor ratio and kurtosis , to decide if Achilles Therapeutics PLC will be following its price patterns.
Risk-Adjusted Performance
5 of 100
Weak | Strong |
Modest
Compared to the overall equity markets, risk-adjusted returns on investments in Achilles Therapeutics PLC are ranked lower than 5 (%) of all global equities and portfolios over the last 90 days. Despite quite weak technical indicators, Achilles Therapeutics may actually be approaching a critical reversion point that can send shares even higher in March 2025. ...more
1 | Syncona Portfolio Ltds Strategic Acquisition of Autolus Therape - GuruFocus.com | 11/15/2024 |
2 | Achilles Therapeutics receives Nasdaq notice for non-compliance - MSN | 01/27/2025 |
| Begin Period Cash Flow | 173.4 M | |
| Free Cash Flow | -49.5 M |
Achilles |
Achilles Therapeutics Relative Risk vs. Return Landscape
If you would invest 102.00 in Achilles Therapeutics PLC on November 2, 2024 and sell it today you would earn a total of 10.00 from holding Achilles Therapeutics PLC or generate 9.8% return on investment over 90 days. Achilles Therapeutics PLC is currently generating 0.191% in daily expected returns and assumes 2.6517% risk (volatility on return distribution) over the 90 days horizon. In different words, 23% of stocks are less volatile than Achilles, and 97% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Achilles Therapeutics Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Achilles Therapeutics' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Achilles Therapeutics PLC, and traders can use it to determine the average amount a Achilles Therapeutics' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.072
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ACHL | |||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns |
Estimated Market Risk
| 2.65 actual daily | 23 77% of assets are more volatile |
Expected Return
| 0.19 actual daily | 3 97% of assets have higher returns |
Risk-Adjusted Return
| 0.07 actual daily | 5 95% of assets perform better |
Based on monthly moving average Achilles Therapeutics is performing at about 5% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Achilles Therapeutics by adding it to a well-diversified portfolio.
Achilles Therapeutics Fundamentals Growth
Achilles Stock prices reflect investors' perceptions of the future prospects and financial health of Achilles Therapeutics, and Achilles Therapeutics fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Achilles Stock performance.
| Return On Equity | -0.44 | ||||
| Return On Asset | -0.27 | ||||
| Current Valuation | (34.59 M) | ||||
| Shares Outstanding | 41.1 M | ||||
| Price To Earning | 0.49 X | ||||
| Price To Book | 0.45 X | ||||
| EBITDA | (70.44 M) | ||||
| Net Income | (69.94 M) | ||||
| Cash And Equivalents | 201.6 M | ||||
| Cash Per Share | 4.94 X | ||||
| Total Debt | 4.62 M | ||||
| Debt To Equity | 0.04 % | ||||
| Current Ratio | 11.45 X | ||||
| Book Value Per Share | 3.46 X | ||||
| Cash Flow From Operations | (48.45 M) | ||||
| Earnings Per Share | (1.66) X | ||||
| Market Capitalization | 47.84 M | ||||
| Total Asset | 161.46 M | ||||
| Retained Earnings | (259.95 M) | ||||
| Working Capital | 128.64 M | ||||
About Achilles Therapeutics Performance
By examining Achilles Therapeutics' fundamental ratios, stakeholders can obtain critical insights into Achilles Therapeutics' financial health, operational efficiency, and overall profitability. These insights assist in making well-informed investment and management decisions. For example, a high Return on Assets and Return on Equity would indicate that Achilles Therapeutics is effectively utilizing its assets and equity to generate significant profits, enhancing its appeal to investors. On the other hand, low ROA and ROE values could reveal issues in asset and equity management, highlighting the need for operational improvements.
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.50) | (0.52) | |
| Return On Capital Employed | (0.60) | (0.63) | |
| Return On Assets | (0.50) | (0.52) | |
| Return On Equity | (0.56) | (0.59) |
Things to note about Achilles Therapeutics PLC performance evaluation
Checking the ongoing alerts about Achilles Therapeutics for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Achilles Therapeutics PLC help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Achilles Therapeutics may become a speculative penny stock | |
| Net Loss for the year was (69.94 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Achilles Therapeutics PLC currently holds about 201.6 M in cash with (48.45 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 4.94, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Achilles Therapeutics has a poor financial position based on the latest SEC disclosures | |
| Roughly 59.0% of the company shares are held by institutions such as insurance companies | |
| Latest headline from news.google.com: Achilles Therapeutics receives Nasdaq notice for non-compliance - MSN |
- Analyzing Achilles Therapeutics' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Achilles Therapeutics' stock is overvalued or undervalued compared to its peers.
- Examining Achilles Therapeutics' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Achilles Therapeutics' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Achilles Therapeutics' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Achilles Therapeutics' stock. These opinions can provide insight into Achilles Therapeutics' potential for growth and whether the stock is currently undervalued or overvalued.
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Achilles Therapeutics PLC. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in rate. You can also try the Volatility Analysis module to get historical volatility and risk analysis based on latest market data.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Achilles Therapeutics. If investors know Achilles will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Achilles Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Achilles Therapeutics PLC is measured differently than its book value, which is the value of Achilles that is recorded on the company's balance sheet. Investors also form their own opinion of Achilles Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Achilles Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Achilles Therapeutics' market value can be influenced by many factors that don't directly affect Achilles Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Achilles Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Achilles Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Achilles Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.